Last updated: March 1, 2026
What is NDC 78206-0141?
NDC 78206-0141 identifies a specific drug product, which corresponds to Rituximab (marketed as Rituxan). This monoclonal antibody targets CD20 and is used primarily for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune conditions.
Market Overview
Market Size and Demand
- The global Rituximab market was valued at approximately USD 6.5 billion in 2022.
- The compound annual growth rate (CAGR) is expected to be 5.3% from 2023 to 2028.
- Demand driven by expanding indications, longer treatment durations, and ongoing adoption in autoimmune diseases.
Key Players
- Roche/Genentech: Original manufacturer.
- Samsung Bioepis and Celltrion: Biosimilar entrants licensed in multiple markets.
- Other Biosimilar Manufacturers: Increasing competition as patents expire.
Patent Landscape
- Roche’s patents expired or are expiring between 2023 and 2028, opening the market for biosimilars.
- Biosimilars are expected to account for an increasing share of total Rituximab sales, potentially reaching 35%-50% by 2028.
Regulatory and Market Access
- Approval pathways for biosimilars in the U.S., Europe, and Asia streamline entry.
- Payer policies favor biosimilars due to lower costs, impacting market share distribution.
Price Trends and Projections
Current Pricing
| Region |
Brand (Rituxan) |
Estimated Price (per 100 mg) |
Biosimilar (average) |
Estimated Price (per 100 mg) |
| U.S. |
Rituxan |
USD 2,500 |
USD 1,800 |
USD 1,200 |
| Europe |
Mabthera |
EUR 2,200 (~USD 2,430) |
EUR 1,700 (~USD 1,870) |
EUR 1,200 (~USD 1,320) |
| Asia |
Rituximab |
USD 3,500 |
USD 2,300 |
USD 1,500 |
Future Price Trends
- Biosimilar prices are expected to decline further by 20%-30% over the next five years.
- Brand-name Rituximab prices are likely to stabilize or slowly decrease due to increased biosimilar competition and negotiated discounts.
- The price for 100 mg vials could fall to approximately USD 800-1,000 in the U.S. and Europe by 2028.
Factors Impacting Prices
- Market Penetration of Biosimilars: Biosimilar adoption reduces overall market prices.
- Regulatory Developments: Faster approval pathways or incentives may hasten biosimilar entry.
- Reimbursement Policies: Payer negotiations and formulary placements influence net prices.
- Manufacturing Costs: Biologics manufacturing remains complex, limiting rapid price reductions.
Competitive Landscape and Market Share
| Manufacturer |
Product |
Estimated Market Share (2023) |
Price Position |
Notes |
| Roche/Genentech |
Rituxan (BRAND) |
60% |
USD 2,500/kg |
Remains dominant in U.S., Europe |
| Samsung Bioepis |
Rezura, Ruxience (BIOSIMILAR) |
20% |
USD 1,200-1,400 |
Growing in U.S. and Europe |
| Celltrion |
Truxima (BIOSIMILAR) |
10% |
USD 1,200 |
Increasing presence |
| Other biosimilar entrants |
Multiple |
10% |
USD 1,000-1,200 |
Market fragmentation |
Key Market Dynamics
- Biosimilar entry has driven price reductions and increased access.
- Payers favor biosimilars, leading to formulary shifts.
- Ongoing patent litigations and legal challenges shape the competitive landscape.
- Development of biosimilar manufacturing facilities worldwide increases capacity and further influences pricing.
Summary of Price Projections (2023–2028)
| Year |
Estimated Brand Price (USD per 100 mg) |
Biosimilar Price Range (USD per 100 mg) |
| 2023 |
2,500 |
1,200 - 1,400 |
| 2024 |
2,400 |
1,100 - 1,300 |
| 2025 |
2,300 |
1,000 - 1,200 |
| 2026 |
2,200 |
900 - 1,100 |
| 2027 |
2,100 |
800 - 1,000 |
| 2028 |
2,000 |
800 - 1,000 |
Note: Prices are approximate and heavily dependent on regional market dynamics and negotiated discounts.
Conclusion
The Rituximab market, represented by NDC 78206-0141, is transitioning toward biosimilar dominance in major markets. Prices are expected to decline gradually over the next five years. Market forces, patent expirations, and regulatory policies will continue steering the landscape, with biosimilars gaining share and exerting downward pressure on the overall pricing environment.
Key Takeaways
- Biosimilars will constitute over 50% of Rituximab sales in developed regions by 2028.
- Prices for biosimilars are projected to fall by up to 30% from current levels.
- Patent expirations from 2023 onward facilitate increased biosimilar competition.
- Price reductions will be driven by payer policies and market entry speed.
- Regional differences affect pricing, with U.S. and European markets exhibiting higher nominal costs.
FAQs
1. Will Rituximab prices return to initial levels after biosimilar entry?
No, biosimilar competition will keep prices lower. Brand prices may stabilize but are unlikely to revert to pre-biosimilar levels.
2. Which regions will see the steepest price declines?
Europe and the U.S. are projected to experience the steepest declines due to early biosimilar adoption and aggressive payer negotiations.
3. How will patent expirations impact the market?
Patents expiring between 2023 and 2028 allow biosimilar manufacturers to launch competing products, increasing market competition.
4. Are biosimilars approved in low- and middle-income countries?
Yes, approval processes are developing, but adoption depends on regulatory capacity, reimbursement, and market incentives.
5. What is the outlook for new indications for Rituximab?
Expanded indications could prolong the product lifecycle and sustain demand, impacting future price stability.
References
[1] MarketWatch. (2023). Rituximab Market Size, Share & Trends.
[2] EvaluatePharma. (2022). Oncology Biosimilar Market Report.
[3] FDA. (2023). Pathway for Biosimilar Approval.
[4] European Medicines Agency. (2022). Biosimilar Medicines in Europe.
[5] IQVIA. (2023). Global Biopharmaceutical Pricing Analysis.
